These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29784451)

  • 1. Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.
    Tao Y; Faivre L; Laprie A; Boisselier P; Ferron C; Jung GM; Racadot S; Gery B; Even C; Breuskin I; Bourhis J; Janot F
    Radiother Oncol; 2018 Sep; 128(3):467-471. PubMed ID: 29784451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent.
    Tortochaux J; Tao Y; Tournay E; Lapeyre M; Lesaunier F; Bardet E; Janot F; Lusinchi A; Benhamou E; Bontemps P; Maingon P; Calais G; Daly-Schveitzer N; Verrelle P; Bourhis J
    Radiother Oncol; 2011 Jul; 100(1):70-5. PubMed ID: 21741720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
    Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
    Vargo JA; Kubicek GJ; Ferris RL; Duvvuri U; Johnson JT; Ohr J; Clump DA; Burton S; Heron DE
    Laryngoscope; 2014 Jul; 124(7):1579-84. PubMed ID: 24123056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck.
    Awan MJ; Nedzi L; Wang D; Tumati V; Sumer B; Xie XJ; Smith I; Truelson J; Hughes R; Myers LL; Lavertu P; Wong S; Yao M
    Ann Oncol; 2018 Apr; 29(4):998-1003. PubMed ID: 29346519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.
    Magrini SM; Buglione M; Corvò R; Pirtoli L; Paiar F; Ponticelli P; Petrucci A; Bacigalupo A; Crociani M; Lastrucci L; Vecchio S; Bonomo P; Pasinetti N; Triggiani L; Cavagnini R; Costa L; Tonoli S; Maddalo M; Grisanti S
    J Clin Oncol; 2016 Feb; 34(5):427-35. PubMed ID: 26644536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer.
    Rühle A; Sprave T; Kalckreuth T; Stoian R; Haehl E; Zamboglou C; Laszig R; Knopf A; Grosu AL; Nicolay NH
    Radiat Oncol; 2020 Apr; 15(1):81. PubMed ID: 32299456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study.
    Heron DE; Rwigema JC; Gibson MK; Burton SA; Quinn AE; Ferris RL
    Am J Clin Oncol; 2011 Apr; 34(2):165-72. PubMed ID: 20686406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.
    Lartigau EF; Tresch E; Thariat J; Graff P; Coche-Dequeant B; Benezery K; Schiappacasse L; Degardin M; Bondiau PY; Peiffert D; Lefebvre JL; Lacornerie T; Kramar A
    Radiother Oncol; 2013 Nov; 109(2):281-5. PubMed ID: 24262821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer.
    Chitapanarux I; Tharavichitkul E; Kamnerdsupaphon P; Pukanhapan N; Vongtama R
    J Radiat Res; 2013 Nov; 54(6):1110-7. PubMed ID: 23740894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
    Strojan P; Grašič Kuhar C; Žumer B; Kadivec M; Karner K; Fajdiga I; Jančar B; Gale N; Poljak M; Kocjan BJ; Zakotnik B
    Head Neck; 2014 Nov; 36(11):1555-61. PubMed ID: 24123552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
    Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
    Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Kochanny SE; Worden FP; Adkins DR; Lim DW; Bauman JE; Wagner SA; Brisson RJ; Karrison TG; Stadler WM; Vokes EE; Seiwert TY
    Cancer; 2020 May; 126(10):2146-2152. PubMed ID: 32073648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck.
    Dornoff N; Weiß C; Rödel F; Wagenblast J; Ghanaati S; Atefeh N; Rödel C; Balermpas P
    Strahlenther Onkol; 2015 Aug; 191(8):656-64. PubMed ID: 26004121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
    Jimeno A; Shirai K; Choi M; Laskin J; Kochenderfer M; Spira A; Cline-Burkhardt V; Winquist E; Hausman D; Walker L; Cohen RB
    Ann Oncol; 2015 Mar; 26(3):556-61. PubMed ID: 25524478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
    Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
    Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
    Soulières D; Aguilar JL; Chen E; Misiukiewicz K; Ernst S; Lee HJ; Bryant K; He S; Obasaju CK; Chang SC; Chin S; Adkins D
    BMC Cancer; 2016 Jan; 16():19. PubMed ID: 26768732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-irradiation with 36 Gy (1.5 Gy Twice Daily) Plus Paclitaxel for Advanced Recurrent and Previously Irradiated SCCHN is Feasible.
    Rades D; Bartscht T; Idel C; Hakim SG
    Anticancer Res; 2018 Jan; 38(1):519-523. PubMed ID: 29277818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results.
    Balermpas P; Keller C; Hambek M; Wagenblast J; Seitz O; Rödel C; Weiss C
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e377-83. PubMed ID: 22414284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.